| Typicality: | 0.313 |
| Saliency: | 0.149 |
| at the national institutes of health | 7 | location |
| therapy → be investigated in → second phase 1/2 trial | 7 |
| negative | neutral | positive |
| 0.014 | 0.926 | 0.059 |
| Raw frequency | 7 |
| Normalized frequency | 0.149 |
| Modifier score | 0.500 |
| Perplexity | 30.474 |